Our lawyers are now investigating Zantac cancer lawsuits. There is a widespread belief amount mass tort attorneys that these cases could be worth billions of dollars. So many people are using this drug. And it may be that Zantac is causing many different types of cancer.
Zantac is a hugely popular drug that is used by millions of people in the U.S. to treat heartburn, acid reflux and similar conditions. In September 2019 the Food and Drug Administration (FDA) announcing that dangerously high levels of a human carcinogen called NDMA have been found in Zantac.
This means that millions of people who have been taking Zantac may have been regularly ingesting a chemical that is notorious for causing cancer. Moreover, drug manufacturers may have known about this risk. And said nothing.
Zantac is manufactured and distributed in the U.S. by the international pharmaceutical giant Sanofi (f/k/a Sanofi-Aventis). The first Zantac class-action lawsuit has already been filed against Sanofi in the U.S. District Court in California. Thousands of additional Zantac lawsuits are expected to follow. My firm is currently accepting new Zantac lawsuit clients.
Zantac is the popular brand name of a drug called Ranitidine which is widely used to treat various gastrointestinal conditions such as heartburn and acid reflux. Zantac has been around for a long time. Zantac was first sold in the U.S. back in 1983 and it quickly became one of the most widely used drugs on the market. Just 3 years after its initial release, Zantac became the first drug in the U.S. to generate $1 billion in sales.
Today Zantac is available in both prescription and over-the-counter form and it remains one of the most popular drugs on the market. In 2018, sales of over-the-counter Zantac alone totaled $129 million.
Ranitidine (the active ingredient in Zantac) belongs to a family of drugs known as histamine-2 or H2 blockers. The over-the-counter dosage of Ranitidine is widely used to treat and prevent chronic heartburn and acid reflux. Prescription-strength Ranitidine is used for the treatment of stomach ulcers and other more serious conditions. Generic versions of Ranitidine are sold by various companies, but Zantac continues to be the most popular brand.
Zantac Found to Contain NDMA
N-Nitrosodimethylamine (“NDMA”) is a chemical byproduct of certain industrial processes NDMA has long been recognized as a potent human carcinogen. NDMA is highly toxic to the human body, especially the liver, and has been conclusively linked to various forms of cancer since the 1970s.
In 2018 Chinese pharmaceutical manufacturers unexpectedly discovered that large quantities of generic Valsartan (a very popular blood pressure drug) were contaminated with high NDMA levels. The presence of NDMA was believed to be an inadvertent byproduct of a change in the manufacturing process. The discovery NDMA in Valsartan promoted a massive safety recall and led to concerns about NDMA contamination in other pharmaceuticals.
Valisure is a pharmaceutical testing laboratory that periodically analyzes drugs for purity and quality. After the Valsartan contamination, Valisure started testing a number of heartburn drugs to check for NDMA. The results of the Valisure testing on heartburn drugs dropped on bombshell on the pharmaceutical community. Valisure found that Zantac and other generic versions of Ranitidine contained dangerously high levels NDMA. In fact, the Valisure testing found that a single tablet of Zantac contained 26,000 times the acceptable daily limit of NDMA. Valisure reported these findings to the FDA in June 2019.
In September 2019, the FDA issued a public safety warning stating that Zantac and generic Ranitidine contained “unacceptable” levels of NDMA.
In response, the 3 largest retail pharmacy stores in the U.S. (Rite Aid, CVS, and Walgreens) have pulled Zantac and its generic alternatives from their shelves. Many manufacturers of generic Zantac have already recalled their products. To date, however, Sanofi has not issued a safety recall of Zantac.
What Are the Potential Injuries from Zantac?
There is no debate within the scientific and medical community that NDMA is a substance that causes cancer in humans and animals. The link between NDMA and various types of cancer was first discovered back in the 1970s. Prolonged exposure to NDMA has been shown to cause a number of cancers including liver, gastric, kidney, and colorectal cancer.
NDMA not only causes cancer but at very high levels it can actually function as a poison. There are several reported cases in which acute, high-dose ingestion of NDMA has caused liver damage, internal bleeding and death. Animal testing found that ingestion of moderate to high levels of NDMA in water or food can damage the liver after just a few weeks.
So what exactly are the plaintiffs’ contending in this case? Is everyone who took Zantac going to get cancer? Of course not. The reasons why people get cancer are complex and not fully understood. But plaintiffs’ argument in these cases is more like this:
So for some people, exposure to these NDMAs is what pushes them off the cliff from not having cancer to having cancer.
What Are the Zantac Lawsuits About?
Sanofi and generic Zantac manufacturers are now facing massive liability from potentially hundreds of thousands of prospective claimants. The first Zantac class-action lawsuit was filed against Sanofi last month in a Federal Court in California. That lawsuit (Garza v. Sanofi-Adventis U.S.) will undoubtedly be the first of hundreds, possibly thousands of Zantac lawsuits to be filed over the next few years.
Who Can File a Zantac Lawsuit?
- Stomach Cancer
- Bladder Cancer
- Liver Cancer
- Kidney Cancer
- Small Intestine Cancer
- Colorectal Cancer
- Esophageal Cancer
It may take years for NDMA exposure to cause any of these cancers to develop. Other potential Zantac plaintiffs include individuals who frequently used Zantac and suffered acute damage to their liver.
What Is the Settlement Value of Zantac Cancer Claims?
Of course, the most honest answer at this point is that I have no idea. If your case were to go to trial, the settlement value would be very different and higher than if you are a part of an eventual global settlement of all Zantac claims.
Speculating at this point is not a very useful exercise. But let’s do it anyway. If the litigation goes very well, the number I would pull out of thin air is $500,000 a case for a mass tort settlement. Why? That is the number we have picked as an average for the Roundup lawsuits a far more mature litigation where the settlement numbers are easier to predict and the loss is cancer.
If your case were to go to trial, the upside would be much might. Again, looking at the Roundup verdicts which have been up to $1 billion (although reduced by a judge). Of course, if the case goes to trial, there is also the risk of getting a zero verdict.
I think Roundup is a good comparable although I do think juries will not be as angry at the Zantac defendants as they are Bayer.
I think I’ve put in enough qualifiers but I’ll say it one more time. All of this is naked speculation. No one knows where these Zantac cancer lawsuits are ultimately going. But there is no question that there are many lawyers out there who believe these claims will result in significant compensation in an eventual global MDL class action settlement.
Contact Miller & Zois About Zantac
If you are one of the millions of people who used Zantac for heartburn, acid reflux or other conditions, you may have been injured by prolonged exposure to NDMA. Thousands of Zantac lawsuits will be filed over the next few years. If you think you may have developed cancer or otherwise been injured by using Zantac contact the dangerous drug lawyers at Miller & Zois today. We can investigate your case and evaluate whether you have a viable claim. Call 800-553-600o or get advice from us for free online.